Tengion
Clinical-stage biotechnology company developing neo-organs and neo-tissues.
Launch date
Market cap
CAD23.6k
Enterprise valuation
CAD39m (Public information from Sep 2024)
Share price
€0.00001 TNGNQ
Washington District of Columbia (HQ)
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$39.0m | Series A | ||
$50.0m | Series B | ||
$33.0m | Series C | ||
N/A | $21.0m | Series C | |
N/A | N/A | IPO | |
$31.4m | Post IPO Equity | ||
N/A | $15.0m | Post IPO Debt | |
N/A | $74.3m | Post IPO Debt | |
* | N/A | N/A | Bankruptcy |
Total Funding | CAD195m |
Recent News about Tengion
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.